Inhibikase Therapeutics, INC. 8-K Filing
Ticker: IKT · Form: 8-K · Filed: Nov 21, 2025 · CIK: 1750149
Sentiment: neutral
Filing Stats: 1,796 words · 7 min read · ~6 pages · Grade level 12.7 · Accepted 2025-11-21 16:28:08
Key Financial Figures
- $0.001 — nge on which registered Common Stock, $0.001 par value IKT The Nasdaq Stock Mark
- $1 — ffered and sold at an offering price of $1.45, and each Pre-Funded Warrant was off
- $0 — an initial exercise price per share of $0.001, subject to certain adjustments. Th
- $93.6 m — from the Offering will be approximately $93.6 million, after deducting underwriting dis
- $107.7 m — ing expenses payable by the Company, or $107.7 million, if the underwriters exercise the
Filing Documents
- d65626d8k.htm (8-K) — 40KB
- d65626dex11.htm (EX-1.1) — 261KB
- d65626dex41.htm (EX-4.1) — 65KB
- d65626dex42.htm (EX-4.2) — 13KB
- d65626dex43.htm (EX-4.3) — 15KB
- d65626dex51.htm (EX-5.1) — 10KB
- g65626g1121233653087.jpg (GRAPHIC) — 3KB
- 0001193125-25-291443.txt ( ) — 630KB
- ikt-20251120.xsd (EX-101.SCH) — 3KB
- ikt-20251120_lab.xml (EX-101.LAB) — 18KB
- ikt-20251120_pre.xml (EX-101.PRE) — 11KB
- d65626d8k_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: November 21, 2025 INHIBIKASE THERAPEUTICS, INC. By: /s/ Mark Iwicki Mark Iwicki Chief Executive Officer